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Rheumatoid arthritis (RA) is a chronic inflammatory disease characterized by
synovial joint inflammation and cartilage and bone tissue destruction. Although 
there exist some treatment strategies for RA, they are not completely safe and
effective. Therefore, it is important to develop and test new drugs for RA that
specifically target inflamed/swollen joints and simultaneously attenuate other 
possible damages to healthy tissues. Nanotechnology can be a good alternative
to consider when envisioning precise medication for treating RA. Through the
use of nanoparticles, it is possible to increase bioavailability and bioactivity of 
therapeutics and enable selective targeting to damaged joints. Herein, recent
studies using nanoparticles for the treatment of RA, namely with liposomes,
polymeric nanoparticles, dendrimers, and metallic nanoparticles, have been
reviewed. These therapeutic strategies have shown great promise in improving
the treatment over that by traditional drugs. The results of these studies confirm
that feasibility of the use of nanoparticles is mainly due to their biocompatibility,
low toxicity, controlled release, and selective drug delivery to inflamed tissues
in animal RA models. Therefore, it is possible to claim that nanotechnology will,
in the near future, play a crucial role in advanced treatments and patient-specific 




Rheumatoid arthritis (RA) is a chronic inflammatory 
disease that affects approximately 1% of the general 
population worldwide, and is associated with a high 
degree of morbidity and significant mortality [1, 2]. It 
is characterized by synovial joint inflammation and 
stiffness, and destruction of cartilages and bones [3, 4]. 
The synovial joint structure changes substantially in 
patients with RA. RA is characterized by an initial 
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pre-vascular inflammatory phase, followed by a 
vascular phase with increase in vessel growth. The 
normal synovial membrane becomes hyperplastic, 
containing a superficial layer of synovial fibroblast 
and macrophages, overlying an interstitial zone that 
comprises of a marked cellular infiltrate, including 
synovial fibroblasts, macrophages, mast cells, CD4+ 
T-cells, CD8+ T-cells, natural killer (NK) cells, NKT 
cells, B-cells, and plasma cells [5]. Inflammation of the 
synovium invades adjacent cartilage, and subsequently 
promotes articular destruction. Articular damage is 
featured by a hypoxic environment and angiogenesis 
(growth of new blood vessels), characteristics of RA 
in joints. The increased number of blood vessels is 
associated with synovial cell hyperplasia and mono-
nuclear cell infiltration. This allows cells to migrate 
from blood into the inflamed synovium, where pro- 
inflammatory cytokines and chemokines play an 
important role in the pathogenesis of RA [6–8]. Many 
types of cells have been identified as important par-
ticipants in the establishment and progression of the 
disease. T-cells have been implicated as the primary 
mediators in the pathogenesis of RA, since they 
contribute to the inflammatory response through 
elaboration of cytokines and interaction with other 
cells that perpetuate the inflammation and joint 
destruction [7]. Pro-inflammatory cytokine tumor 
necrosis factor-α (TNF-α) also has an important role 
in the pathogenesis of RA. It has been shown to be  
a therapeutic target, since anti-TNF-α agents could 
induce long-term improvements in the RA symptoms, 
by protecting the affected joints from tissue 
degradation [8].  
The treatment strategies for RA comprise of the 
disease-modifying anti-rheumatic drugs (DMARDs), 
typically supported by non-steroidal anti-inflammatory 
drugs (NSAIDs) and/or corticosteroids, in order to 
reduce joint inflammation and pain, maximize joint 
function, and prevent joint destruction and deformity. 
Agents that target TNF-α are the leading biological 
DMARDs. There are three TNF inhibitors well 
established in the RA market: (i) infliximab, (ii) a 
chimeric monoclonal antibody, and (iii) the fusion 
protein etanercept [9, 10]. Despite recent advances in 
medical therapeutics, the treatments still raise major 
efficiency concerns. In fact, patients fail to respond 
adequately, or become resistant to drug therapy and 
long-term use of these drugs, probably due to adverse 
events, such as tuberculosis, fungal infections, 
lymphomas, liver injury, myelosuppression, and heart 
failure. Therefore, it is urgent to develop and test new 
drugs to specifically target inflamed joint, and attenuate 
damage to healthy tissues. In this regard, nanomedicine 
is a promising therapeutic approach for RA. Drug- 
loaded nanocarriers, coupled with pathophysiological 
characteristics of inflamed joints, can amplify the 
bioavailability and bioactivity of medical therapeutics 
and possibly promote selective targeting of inflamed 
joints [11]. 
Encapsulating bioactive agents into nanocarriers 
that selectively deliver drugs to the intended sites of 
action may be achieved through targeted approaches 
that will be overviewed herein [7]. 
2 Nanoparticle systems 
Nanotechnology refers to the ability to measure, 
design, and manipulate materials at atomic, molecular, 
and supramolecular level [12, 13]. The production   
of nanomaterials for drug delivery can offer new 
opportunities to provide more focused and precise 
treatment of the disease at molecular level, and improve 
the potential therapeutic by reducing its toxicity and 
enhancing effectiveness. Most drugs are limited   
by their poor solubility, high toxicity, high dosage, 
nonspecific delivery, and short circulating half-lives. 
Nano-size drug delivery focuses on the preparation 
of bioactive molecules in biocompatible nanosystems, 
such as nanoparticles (NPs) [14, 15]. 
NPs have sizes ranging from 1–100 nm. The 
therapeutic applications of NPs are diverse. One major 
advantage is the improvement of solubility of poorly 
water-soluble drugs. NPs of poorly water-soluble drugs 
can increase the surface area and surface interactions 
of the NPs, thereby enhancing the dissolution rate and 
allowing control of the pharmacokinetic properties of 
the dosage form [16]. NPs also prolong the half-life of 
systemic circulation of the drug, release drugs at a 
sustained rate, deliver drugs in a targeted manner to 
minimize systemic side effects, and deliver two or 
more drugs simultaneously for combination therapy. 
Drugs, used in the treatment of RA, are characterized 
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by anti-inflammatory and analgesic effect and reduction 
of inflammatory markers. Drugs such as clodronate, 
triptolide, methotrexate, indomethacin, dexamethasone 
(DEX), and small interfering RNA (siRNA) against 
TNF can be loaded onto NPs by either attaching them 
to the nanocarrier surface or by encapsulating them 
within. NPs have been used as drug-delivery systems, 
with unique architectures, to work as a specific vehicle 
for a particular disease treatment. These technologies 
have been studied and used for the treatment of 
cancer, diabetes, pain, asthma, allergy, and infection 
[12–15, 17]. There are different types of nanoparticles 
including polymeric NPs, liposomes, dendrimers, 
magnetic NPs, metallic NPs, polymeric micelles, solid 
lipid nanoparticles, and nanotubes [13, 18, 19] (Fig. 1). 
The most studied nanoparticles for treating RA are 
liposomes, polymeric NPs, dendrimers, and metallic 
nanoparticles.  
2.1 Liposomes 
Liposomes are spherical nanoparticles constituted of 
bilayer membranes, which are composed of synthetic 
or natural phospholipids, with an aqueous interior. 
Physical and chemical properties of a liposome include 
permeability, charge density, and steric hindrance. 
They can be used as effective drug delivery systems; 
drugs may be loaded either in the aqueous com-
partment or in the lipid membrane. Generally, lipid 
soluble drugs are incorporated in the liposomal 
 
Figure 1 Schematic of the nanoparticle systems. (a) Polymeric 
NPs, (b) liposomes, (c) dendrimers, (d) magnetic NPs, (e) metallic 
NPs, (f) polymeric micelles, (g) solid lipid nanoparticles, and (h) 
nanotubes.  
membrane while water soluble drugs are loaded in 
the compartment [20, 21].  
There have been many studies reporting the potential 
applications of liposomes in RA treatment (Table S1 
in the Electronic Supplementary Material (ESM)). Fong 
et al. [22] studied rabbits (with and without arthritis) 
injected with either free [3H] methotrexate ([3H]MTX) 
or liposomes containing [3H]MTX with thioglycollate- 
elicited macrophages in vitro. These authors found that 
although the catchment of liposomes by the synovium 
was low, a 40-fold increase in drug retention at the 
joint was reported, compared to that when free MTX 
was injected. Liposomes can improve the efficacy and 
decrease the side effects of drugs in the joint cavity 
[23, 24]. 
Love and coworkers [25] have studied the effect  
of liposomes in the inflamed tissues of rats, with and 
without induced arthritis. Control rats and those 
with arthritis were injected intravenously, via the tail 
vein, with four different-sized liposome preparations. 
This study could verify that there was 10 times more 
liposome accumulation in the diseased rats than in 
control rats, and there were differences between 
small unilamellar vesicle and multilamellar vesicle 
accumulation in inflamed and control paws; small 
unilamellar vesicles were accumulated more in the 
inflamed paws. Another study investigated whether 
local removal of phagocytic synovial lining cells (SLCs) 
from the knee by clodronate-liposomes before the 
introduction of collagen-induced arthritis (CIA) had 
an effect on the development of cartilage destruction. 
The study showed that phagocytic SLCs depleted  
by a single injection of clodronate-liposomes in the 
knee joint, accompanied by SLCs treated with DEX, 
decreased cartilage damage [24, 26–28].  
Williams et al. [29] studied the effect of liposome- 
encapsulated methotrexate in the inflamed knee joint 
to determine if this conjugation would be able to 
modulate the severity of induced arthritis in rats. The 
conjugation has been shown to inhibit the release of 
two pro-inflammatory mediators, TNF- and prostag-
landin (PGE2)-stimulated rat peritoneal macrophages 
in vitro. After the onset of joint inflammation, the 
rats were treated intravenously with liposome- 
methotrexate. Liposome encapsulating methotrexate 
showed significant improvement in the established 
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joint inflammation and less toxicity than comparable 
doses of the free drug.  
A study by Watson-Clark et al. [30] examined the 
use of liposomes as a boron delivery method in rats 
with CIA. The concentration of boron, delivered by 
liposomes, was determined after intravenous injection 
of liposomes. The bio-distribution of liposomes incor-
porated in the vesicle membrane demonstrated higher 
synovium/blood boron ratios, reduced boron uptake in 
synovial tissue, and more rapid blood clearance [28]. 
Another study analyzed the effect of liposomal 
benzoporphyrin derivative-monoacid ring A (BPD- 
MA or BPD verteporfin) on the inflamed synovium 
and articular and peri-articular tissues following its 
intravenous and intra-articular administration in 
rabbit model. The study showed that there was a 
preferential distribution of BDP-MA in the inflamed 
synovium and its clearance from the synovium was 
rapid [24, 28, 31] (Fig. 2). 
Highton et al. [32] investigated the involvement of 
clodronate-containing liposomes in anti-macrophage 
treatment for RA. They used the antigen-induced 
arthritis model (AIA) in sheep to evaluate the effect 
of clodronate liposomes. There was an uptake of 
liposomes into the macrophages in the inflamed joint. 
They administered an intra-articular injection of 
clodronate liposome in a group of sheep (group 1), or 
saline liposome (group 2), and another without arthritis 
or treatment (group 3). There was no difference in 
joint diameter or swelling between groups 1 and 2. In 
these groups histologic scoring were similar, and 
both were worse than group 3. Despite the possible 
pro-inflammatory effect, the study was not able to 
 
Figure 2 Scheme for the use of liposomes in rheumatoid arthritis 
(reproduced with permission from Ref. [24], © The Authors 2014). 
prove the therapeutic effect of a single dose of 
clodronate liposomes in this kind of animal model 
[28]. Another investigation explored the subcutaneous 
administration of superoxide dismutase (SOD) 
entrapped in long circulating liposomes in rats with 
RA. Results showed that small-sized SOD-liposomes 
had a higher uptake in the inflamed foot than the 
large-sized ones. When the localization in the inflamed 
foot was compared to that in the non-inflamed foot, 
uptake was higher for the small-sized SOD-liposomes 
than the large-sized SOD-liposomes. Thus, small-sized 
liposomes were found to be more effective than the 
large-sized ones for targeting SOD to arthritic sites 
by subcutaneous administration [28, 33].  
A study made by Srinath et al. [34] investigated  
the encapsulation of indomethacin in liposomes to 
determine its anti-inflammatory potential. The study 
investigated its bio-distribution using conventional 
liposomes and long-circulating liposomes in a rat RA 
model. Long-circulating liposomes showed higher 
targeting efficiency in arthritic paw tissue than con-
ventional liposomes [23, 28].  
Ceponis and coworkers [35] showed that intra- 
articular injection of low doses of liposomal clodronate, 
in rabbits with established AIA, had anti-inflammatory 
and anti-erosive effects. There were low levels of 
TNF, lining cell hyperplasia, and macrophages in the 
synovium of the liposomal clodronate treated group. 
Nevertheless, the effect was temporary, and it did not 
prevent the occurrence of joint erosion over a long 
term [28].  
A study reported by Trif et al. [36] investigated 
the use of liposome-entrapped lactoferrin (hLf) as a 
delivery system to prolong hLf retention at local 
inflammation sites, such as the rheumatoid joint. 
Investigators compared negatively charged liposomes, 
positively charged formulations, and free proteins. In 
vivo studies in rats with CIA showed that the positive 
liposomes were more effective in prolonging the 
residence time of hLf in the inflamed joint compared 
to other liposomes. In 2007, the same research group 
compared the capacity of free lactoferrin and 
encapsulated lactoferrin (in liposomes) to prevent an 
established joint inflammation and to modulate the 
cytokine response of lymph node (LN) T lymphocytes 
in DBA/1 mice with CIA. The anti-inflammatory 
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effect was higher in positive liposomes and inferior in 
the free protein. After a single injection of liposomal 
hLf, the arthritic score was significantly reduced. 
Cytokine levels produced by LN T cells showed a 
decrease of the pro-inflammatory cytokine (TNF), 
followed by an increase of the anti-inflammatory 
cytokine (IL-10), in encapsulated hLf than in free  
hLf [37]. 
Another report had compared a dexamethasone- 
anti-E-selectin immunoconjugate with anti-E-selectin 
immunoliposomes containing DEX, analyzing the 
increase in activated endothelial cells in vivo and 
binding and internalization in vitro. The study showed 
that dexamethasone-anti-E-selectin was internalized 
to a larger extent than the anti-E-selectin immuno-
liposomes, while the high drug-loading capacity of 
the liposomes may allow a larger quantity of DEX  
for intracellular delivery. Both accumulated in the 
activated endothelial cells of inflamed murine skin 
[38, 39].  
Metselaar et al. [40] studied the intravenous 
treatment mechanism of prednisolone phosphate 
(PLP), encapsulated in long-circulating polyethylene 
glycol liposomes, to target inflamed joints in rats with 
AIA. Liposomal PLP proved to be highly effective, 
with complete reduction of the inflammatory response 
unlike the same dose of non-encapsulated PLP 
[27, 28]. In 2004, the same researchers investigated 
the mechanism of action of long PEG-liposome- 
encapsulated PLP in targeting synovial lining cells of 
inflamed joint and of cartilage destruction in mice 
with CIA. Mice were treated with conjugated and 
free PLP few days after establishment of the disease, 
and liposomal PLP resulted in a strong and lasting 
resolution of joint inflammation compared to free 
PLP [7, 41]. A study made by Harigai et al. [42] 
evaluated the potential of prednisolone phosphate 
(PSLP)-containing 3,5-dipentadecyloxybenzamidine 
hydrochloride (TRX-20) liposomes to treat RA. The 
conjugated system was added to HFLS cells. The 
effect of encapsulated PSLP (in TRX-20 liposomes) 
on HFLS cells was evaluated by the inhibition of 
inflammatory cytokine and inflammatory chemokine 
production. The symbiosis of the PSLP-containing 
liposomes with HFLS cells was 40 times higher than 
that of PSLP-containing liposomes without TRX-20 [24].  
Another study investigated if arginylglycylaspartic 
acid (RGD) peptide-expose long circulating polyethylene 
glycol (PEG) liposomes (RGD-PEG-L). The aim of 
this work was to see if αvβ3 integrins, expressed  
on angiogenic vascular endothelial cells (VECs), are 
efficient to connect VECs at sites of inflammation, 
and if liposomes containing dexamethasone phosphate 
(DEXP) could be used as carriers to interfere with the 
development of experimental arthritis. In rats with 
AIA, DEXP-encapsulating RGD-PEG-L was evaluated 
relative to non-targeting liposomes. One intravenous 
injection of DEXP (encapsulated in RGD-PEG-L) 
resulted in a strong and lasting anti-arthritic effect in 
rats with AIA [24, 27, 39, 43]. The folate-linked lipid- 
based nanoparticle delivery of an NFκB decoy into 
murine macrophage RAW264.7 cells was also studied. 
The manifestation of folate receptor in RAW264.7 cells 
activated lipopolysaccharides, as confirmed by the 
suppression of FR mRNA. After being transferred via 
NP-F, NFκB was detected in the cytoplasm and an 
inhibitory effect on the translocation of NFκB to the 
nucleus was observed, presuming that NP-F delivered 
the NFκB into the cytoplasm. This approach is 
important for using active macrophages in gene 
therapy of RA [44].  
Rauchhaus et al. [45] analyzed the effect of 
glucocorticoid dexamethasone phosphate (DXM-P) 
encapsulated in non PEGylated liposomes in rats with 
AIA and those without a drug. Injection of liposomal 
DXM at 6, 24, and 48 h, after arthritis induction, was 
responsible for removing joint swelling. Liposomal 
DXM suppressed both chronic inflammation and 
joint destruction, while free DXM-P failed to prevent 
joint destruction. Richard et al. [46] investigated the 
efficacy of a single dose of liposomal clodronate within 
small unilamellar vesicles (SUVs) to suppress joint 
inflammation and histological progression of AIA in 
rats. Rats received a single injection of liposomal 
clodronate seven days post-arthritis induction. The 
results showed that liposomal clodronate eliminates 
synovial macrophages, reduces inflammation, and 
ameliorates joint destruction in AIA.  
In 2001, Richard et al. [47] investigated the role   
of macrophages, using liposomal clodronate, in the 
pathogenesis of induced chronic arthritis. Ten days after 
arthritis induction, rats received a single intravenous 
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injection of liposomal clodronate in SUVs. Twenty-six 
days after treatment, SUVs suppressed the development 
of arthritis. Macrophage elimination by SUVs was 
found to inhibit local production of IL-1β, IL-6, TNF-α, 
and MMP-9, and hence pathogenesis of inflammatory 
arthritis [28].  
A study made by Simões et al. [48] investigated a 
novel treatment possibility using the SOD liposome 
mixed lipid vesicles, transfersomes (TFs), in a rat 
model of AIA. Treatment of animals started at day 1 
by the epicutaneous application of SOD-TFs. After 
this application, the induced rat paw edema was 
suppressed. It was shown for the first time that SOD 
incorporated into TFs, and applied onto a skin area 
not necessarily close to the inflamed tissue, is able to 
promote non-invasive treatment of induced arthritis 
[24]. Gaspar et al. [49] studied the biological behavior 
of acylated superoxide dismutase (Ac-SOD) enzy-
mosomes (enzymes inserted in the lipid bilayer of 
the liposomes), as compared to SOD located in the 
aqueous compartment of liposomes. For this study, 
unmodified liposomes and long circulating liposomes 
coated with PEG were used. The results showed that 
liposomes coated with PEG were not influenced by 
the insertion of Ac-SOD in the lipid bilayers. The 
therapeutic potential of SOD liposome was compared 
to that of Ac-SOD enzymosomes in rats with arthritis. 
Ac-SOD enzymosomes presented a faster anti- 
inflammatory effect, as observed by volume of the 
inflamed paws. The results allowed the conclusion 
that Ac-SOD enzymosomes are able to exert therapeutic 
effect before liposomal disruption and can perform 
sustained release of the enzymes. Another study 
determined the therapeutic effect of TNF siRNA 
administration using liposomes, in rats with RA. The 
therapeutic effect in rats was assessed after intravenous 
delivery of TNF siRNA by cationic liposomes.   
Rats showed improvements when TNF siRNA was 
administrated, along with the liposome and carrier 
DNA. There was inhibition of systemic TNF secretion 
and decrease in the levels of interleukin-6. The study 
demonstrated the efficiency of liposome carrier system 
to silence TNF-α in rats with RA [28, 50].  
2.2 Polymeric nanoparticles  
Polymeric NPs are biodegradable, biocompatible, and 
efficient drug-delivery systems. These nanoparticles 
exhibit great potential for surface modification and 
functionalization with different ligands, are excellent 
pharmacokinetic controls, and are able to encapsulate 
and deliver a variety of therapeutic agents [15]. There 
are several studies of polymeric nanoparticles for the 
treatment of RA (Table S2 in the ESM). Gerlag et al. 
[51] injected mice with CIA with RGD-containing 
cyclic peptide (RGD-4C) that binds selectively to the 
αvβ3 and αvβ5 integrins in the cells of the inflamed 
synovium, but not in the cells of normal synovium. 
αvβ3 and αvβ5 are important in angiogenesis; αvβ3 
manifests on synovial blood vessels in RA and αv 
antagonists injected directly into the joint quell synovitis. 
The results showed that RGD-4C decreased rheumatoid 
arthritis symptoms and increased apoptosis of synovial 
blood vessels.  
A study by Kim et al. [52] investigated the effect of 
single administration of poly(D,L-lactic/glycolic acid) 
(PLGA) entrapping type II collagen on the development 
of CIA. This conjugate was studied due to the capacity 
of each of its elements to be a strong candidate for 
suppression of autoimmune disease. After a single 
administration of PLGA-CII in mice, the incidence 
and severity of arthritis and CIA were significantly 
reduced. Furthermore, the mice showed a higher 
level of transforming growth factor β (TGFβ) mRNA 
and lower level of TNF-α mRNA expression compared 
to the other groups of mice. Another study evaluated 
the fluoresceinamine-bound PLGA (FA-PLGA) copo-
lymer for its application as an intra-articular delivery 
system in the rat synovium after administering directly 
into the joint cavity. FA-PLGA nanospheres could be 
more befitting for delivery to inflamed synovial tissue 
due to their ability to pass through the synovium 
and provide local therapeutic action in joint diseases 
[53, 54].  
Fienh et al. [55] evaluated the anti-arthritic effect  
of albumin-coupled methotrexate (MTX-HSA) on 
potential target cells for albumin-mediated drug 
delivery. The mouse model of CIA was used to analyze 
the anti-arthritic effects of MTX and MTX-HSA. 
Intravenous administration of the injection showed 
that MTX-HSA is superior to MTX in inhibiting the 
development of CIA and reducing joint destruction 
as well as the number of affected paws. MTX-HSA can 
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be one of the potential target cells for anti-arthritic 
treatment [23, 56].  
A study by Higaki et al. [57] investigated betame-
thasone sodium phosphate (BSP), encapsulated in 
PLGA nanoparticles, to target inflamed joints in rats 
with AIA and in mice with anti-type II collagen 
antibody induced arthritis (AbIA). The rats were 
treated intravenously with PLGA-nanosteroid after 
the initial signs of arthritis; there was a decrease in 
paw inflammation, and a single injection resulted in 
a large decrease of the inflammatory response after 
one week. Furthermore, histological examination 
showed a significant decrease of the inflammatory 
cells in the joints [23, 54, 58]. Another study analyzed 
the anti-inflammatory effect of the triptolide (TP) 
loaded poly (D,L-lactic acid) (PLA) nanoparticles 
(TP-PLA-NPs) in rats with AIA. The results showed 
that TP-PLA-NPs significantly inhibited the adjuvant 
arthritis and had a significant anti-inflammatory effect 
after a long-time administration [58, 59].  
Mansouri et al. [60] studied the synthesis and 
characterization of FA-chitosan-DNA nanoparticles 
and evaluated the cytotoxicity in vitro. Chitosan-DNA 
and FA-chitosan-DNA nanoparticles were made using 
reductive amidation and a complex coacervation 
process. The transfection efficiency depended on various 
factors such as chemical structure of polycations, cell 
type, nanoparticle size, composition, and interaction 
with cells. The results showed that FA-nanoparticles 
had decreased cytotoxicity (damaging property of a 
substance comparatively to cells), accompanied by a 
good DNA condensation and improved cellular uptake 
(around 118 nm) due to the particle size [39].  
A study by Wang et al. [61] investigated 
DEX-HPMA copolymer conjugate to target inflamed 
joints in rats with RA. The investigators administered 
DEX-HPMA in a rat model of AIA and found that 
DEX-HPMA had more anti-inflammatory effect com-
pared to free DEX. Moreover, bone and cartilage 
preservation with the DEX-HPMA treatment was 
higher than that with free DEX treatment [23, 39]. 
Another study investigated nanoparticles coated 
with collagen II-binding-peptide (WYRGRL) to target 
the articular cartilage in RA. Peptide-functionalized 
nanoparticle-targeted articular cartilage was reported 
to be much higher than with nanoparticles presenting 
a scrambled peptide sequence following intra-articular 
injection in the mouse [62].  
Hwang et al. [10] evaluated the use of α- 
methylprednisolone (MP) conjugated cyclodextrin 
polymer-based nanoparticles (CDP) for rheumatoid 
arthritis therapy. The conjugate was administered 
intravenously in rats with CIA. A significant decrease 
in arthritis score was observed in rats treated with 
CDP-MP; histological evaluation after 28 days showed 
decreased synovitis. The study showed that CDP-MP 
may increase the efficacy for rheumatoid arthritis 
treatment [7, 11].  
Another group, Howard et al. [2] investigated 
chitosan/siRNA nanoparticle-mediated TNF-α reduction 
in macrophages for anti-inflammatory treatment in 
mice with CIA. Histological analysis of joints showed 
little cartilage destruction and inflammatory cell 
infiltration in anti-TNF-α-treated mice. This work 
showed that chitosan/siRNA nanoparticle-mediated 
TNF-α knockdown reduces local and systemic 
inflammation.  
Ishihara et al. [4] studied the therapeutic activity 
of betamethasone disodium 21-phosphate (BP) 
encapsulated in nanoparticles of PLGA/PLA homo-
polymers and PEG-block-PLGA/PLA copolymers in 
rats with AIA and mice with AbIA to target their 
inflamed joint. The conjugation was intravenously 
administered. In rats with AIA, there was a 35% 
decrease in paw inflammation with a single injection 
[7, 11, 39]. In 2010, Ishihara et al. [63] investigated the 
degradation of poly lactic acid and monomethoxy 
PEG-polylactide block copolymer along with BP in 
vitro during incubation. BP was found to accumulate 
in the inflammatory lesion of adjuvant arthritis rat 
models and the amount of BP gradually decreased. 
Results suggested that the increase in BP in the lesion 
was due to the increase in permeability and retention 
effect. The internalization in inflammatory macrophages 
was due to the loss of PEG and the release of BP in 
cells with PEG hydrolysis. Another study examined 
PEG-DEX conjugate for the treatment of RA. The 
conjugate was tested in an AIA model. The study 
revealed that a single PEG-DEX conjugate could 
improve the ankle joint inflammation in rats with 
AIA. Histological and bone mineral density analysis 
showed superior anti-inflammatory and disease 
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modifying effects with PEG-DEX conjugate [64].  
A study made by Kim et al. [65] examined the 
efficiency of RA treatment by the development of 
nanocomplexes based on hyaluronic acid (HA) and 
PEG-derivatized TNF-related apoptosis inducing 
ligand) (TRAIL) (PEG-TRAIL). The nanocomplexes 
were prepared by mixing the positively charged 
PEG-TRAIL with negatively charged HA. The in vivo 
bio-distribution and diffusion kinetics of Cy5.5-labeled 
PEG-TRAIL in mice were observed after subcutaneous 
injections. Results showed greater therapeutic effects 
in clinical scores and histology in the delivery of 
PEG-TRAIL, with nanocomplex in 1% HA; furthermore, 
this approach resulted in substantial reduction of 
serum inflammatory cytokines and collagen-specific 
antibodies that are responsible for RA.  
A study performed by Schmitt et al. [66] investigated 
hydrophilic nanogels based on chitosan, with 
hyaluronate surface, loaded with photosensitizers to 
target macrophages. This study showed a selective 
uptake by macrophages and increased retention of 
drugs in the inflamed tissues. While injection-free 
photosensitizers resulted in rapid liberation from the 
joints, nanogel-encapsulated photosensitizers remained 
in the inflamed joints for a longer period of time.  
The last treatment of the inflamed joints resulted in 
reduction of inflammation compared to a standard 
corticoid treatment [39]. Another study investigated 
chitosan conjugated with folate. Chitosan-DNA and 
folate-chitosan-DNA were intravenously injected in 
normal and arthritic rats. This approach was found  
to facilitate the transfection of folate-chitosan-DNA 
nanoparticle and more efficiently decrease inflammation 
in the arthritis rat model [39, 67].  
Scheinman et al. [68] investigated the functionalization 
of RGD-PLGA to deliver a STAT1 siRNA in RA model. 
RGD-PLGA increased both the uptake by paw tissues 
and prolonged delivery of nanoparticles in the arthritis 
mouse model. RA regressed with STAT1 siRNA, and 
STAT1 mRNA levels were lower in the paws of treated 
animals. This conjugate was shown to be effective  
in the treatment of arthritis, through a selective 
inhibition of macrophage and dendritic cell activation. 
Another study investigated whether a metalloproteinase 
(MMP-3)-specific polymeric matrix could be used for 
early diagnosis of arthritis in mice with CIA using a 
near-infrared fluorescence (NIRF) imaging system 
[69]. After intravenous administration of the probe, 
different stages of disease were observed through 
fluorescence imaging. A higher NIRF signal was 
recovered from arthritic joints compared to that from 
normal joints. Immune histochemical analysis and 
western blotting confirmed that fluorescence in the  
in vivo imaging was related to MMP-3 activity in the 
joint tissues [69].  
A study by Park et al. [70] investigated hydro-
phobically modified glycol chitosan nanoparticles 
(HGC) labeled with Cy5.5 (a dye) in mice with CIA. 
Activated macrophages expressing Mac-1 molecules 
effectively phagocyted HGC-Cy5.5 that formed 
spherical nanoparticles under physiologic conditions. 
Previous studies showed that HGC nanoparticles 
mainly accumulate in tumor tissues via leaky vessels, 
which implied that the pathophysiologic properties 
increased permeability and retention effect. Due to the 
abundance of activated macrophages and angiogenesis, 
characterized by permeable and disorganized structure 
within the synovial tissues in RA, the investigators 
hypothesized that HGC nanoparticles may pre-
ferentially accumulate within arthritic joints. Histological 
evaluation confirmed that the mechanism of selective 
accumulation of HGC-Cy5.5 within synovial tissues 
included increased phagocytosis and permeability 
through leaky vessels. Another group, Boekhorst et al. 
[71] evaluated the anti-inflammatory effect of PLGA 
nanoparticles loaded with siRNA against TNF-α. 
Intra-articular treatment in joints with TNF-α siRNA- 
loaded NPs resulted in the disease activity reduction; 
no significant decrease in joint effusions was observed 
as compared to that in the treatment with PLGA NPs 
loaded with non-specific control siRNA. The study 
suggested that HGC-Cy5.5 can play an important role 
as an RA therapeutic. 
Rollet et al. [72] investigated the effect of folic acid- 
human serum albumin nanocapsules (FA-HSA)   
on targeted drug delivery to chronically activated 
macrophages. Some studies showed that the beta 
folate receptor (FRβ) has a high affinity for FA and  
is expressed by activated macrophages. Therefore, 
FA-based nanoparticles can provide the possibility of 
delivering therapeutic agents to activated macrophages 
without affecting normal cells and tissues. FRβ- 
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expressing macrophages were reported to show an 
increased binding for FA-HSA compared to that in 
the absence of FA [56]. Another study developed 
PLGA nanoparticles co-encapsulating MTX and iron 
oxide nanoparticles (SPIONS) for RA therapy and 
imaging applications. The NPs were functionalized 
with anti-CD64 antibody to specifically target 
rheumatoid arthritis-associated macrophages, to decrease 
damage to the tissues. The effect of each component 
(MTX, SPIONS, and antibody) was compared. In vitro 
studies enabled the cytotoxic profiling of NPs. MTX 
indicated high toxicity while MTX-free NPs were only 
toxic when administered at the highest concentration 
based on PLGA’s biocompatibility [73]. 
Kim et al. [74] investigated the self-assembled dextran 
sulphate nanoparticles for targeting rheumatoid arthritis. 
In vivo results showed that these nanoparticles 
selectively accumulated in inflamed synovia of mice 
with CIA, due to their binding to the macrophage 
scavenger receptors that were overexpressed in the 
synovia, thus suggesting the potential of dextran 
sulphate nanoparticles as drug carriers for arthritis 
therapy.  
A study by Heo et al. [75] investigated hyaluronan 
nanoparticles (HA-NPs) carrying a γ-secretase inhibitor 
(DAPT) for rheumatoid arthritis therapy. Results 
demonstrated that DAPT-loaded HA-NPs (DNPs) 
attenuated the severity of RA compared to DAPT 
alone, as evaluated from tissue damage, clinical score, 
and neutrophil infiltration. Furthermore, DNPs reduced 
the production of pro-inflammatory cytokines and 
collagen-specific auto-antibodies in the serum of mice 
with CIA. In mice with AbIA, a single injection ended 
the inflammatory response after one week (Fig. 3). 
Lee et al. [76] designed a nanocomplex of poly-
merized siRNA (poly-siRNA) targeting TNF-α with 
thiolated gycol chitosan (TGC) polymers for the 
treatment of RA. Poly-siRNA was prepared by self- 
polymerization that resulted in nanocomplex of 
polymerized siRNA with thiolated glycol chitosan 
(psi-tGC-NPs). These nanoparticles showed in vitro 
TNF-α gene silencing efficacy and high accumulation 
at the arthritic joint sites in mice with CIA (Fig. 4). 
Another study investigated folic acid-etoricoxib- 
bovine serum albumin nanoparticles (F-ETX-NPs) for 
rheumatoid arthritis treatment [77]. The etoricoxib 
 
Figure 3 Scheme of DNPs in inflamed joint-targeted drug 
delivery (reproduced and adapted with permission from Ref. [75], 
© Elsevier 2014). 
 
Figure 4 Scheme of psi-tGC–NP delivery into macrophages 
leading to TNF-α gene knockdown (reproduced and adapted with 
permission from Ref. [76], © The American Society of Gene & 
Cell Therapy 2014). 
concentration revealed its targeting potential to   
the activated macrophages. The results suggested 
that F-ETX-NPs have the potential to target activated 
macrophages in rheumatoid arthritis, and could   
be used for early stage diagnosis of rheumatoid 
arthritis [77].  
2.3 Dendrimers  
Dendrimers are the most interesting class of synthetic, 
highly branched, and low dispersity macromolecules 
[78]. A typical dendrimer is composed of different 
parts (that confer many advantages) such as, a central 
core and surrounding repeat units that start from the 
core like branches, and multiple peripheral functional 
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groups [79]. The functional groups exhibit a high degree 
of molecular uniformity and confine molecular 
weight distribution, in addition to their adjustable 
size, multivalency, solubility in different media, and 
biodegradation [80].  
Some studies of dendrimers for rheumatoid arthritis 
treatment are reported in Table S3 in the ESM. The 
first study used folate-targeted PEG conjugates of G 
3.5 PAMAM dendrimer as targeted drug delivery 
systems for inflammation, and to investigate its 
distribution standard in arthritic rats. Folate-PEG- 
PAMAM was loaded with indomethacin. Folate-PEG 
conjugation had 10–20 fold increase in drug loading 
efficiency and was found to release indomethacin to 
the joints in a controlled manner. The drug targeting 
efficiency was the highest in folate-PEG conjugate 
compared to that in dendrimers without PEG [81].  
Another study investigated the poly (amidoamine) 
dendrimer (generation 5) nanoparticle conjugated with 
folic acid (FA) and MTX (G5-FA-MTX) as a therapeutic 
for the inflammatory disease of arthritis. In vitro  
and in vivo studies were performed in a rat model of 
CIA in order to evaluate the therapeutic potential   
of G5-FA-MTX. G5-FA-MTX operated as a strong 
anti-inflammatory agent and reduced arthritis-induced 
parameters of inflammation such as paw volume, 
cartilage damage, bone resorption, etc [82] (Fig. 5). 
Hayder et al. [83] explored the therapeutic potential 
of azabisphosphonate (ABP) dendrimer for target 
monocytes in the treatment of rheumatoid arthritis. 
In two animal models, IL-1ra(-/-)mice and mice 
undergoing K/BxN serum transfer, intravenous injec-
tions of ABP dendrimer prevented the development 
of inflammatory arthritis. The study demonstrated 
that intravenous injection of dendrimer diminished 
the inflammatory cytokine levels, normal synovial 
membrane, and default cartilage destruction and 
bone erosion [84] (Fig. 6).  
2.4 Metallic nanoparticles 
Metallic nanoparticles comprise a class of materials 
with very useful properties. These nanoparticles can 
be synthesized and modified with several functional 
groups that allow them to be conjugated with antibodies, 
ligands, magnetic separation, target drug delivery, 
vehicles for gene and drug delivery and diagnostic 
 
Figure 5 Schematic structure of G5-FA-MTX nanoparticle 
(reproduced with permission from Ref. [82], © American College 
of Rheumatology 2011). 
 
Figure 6 Structure of dendrimer ABP (reproduced with 
permission from Ref. [83], © The American Association for the 
Advancement of Science 2011). 
imaging [85, 86]. 
There have been some studies regarding the use  
of metallic nanoparticles such as, gold nanoparticles 
(AuNPs), iron oxide nanoparticles, and silver nano-
particles for the treatment of RA (Table S4 in the ESM). 
Tsai et al. [87] investigated the effect of intra-articular 
delivery of nanogold to target vascular endothelial 
growth factor (VEGF) in rats with CIA. Angiogenesis 
has an important role in RA and nanogold inhibits 
the activity of the angiogenic factor, VEGF. The 
microvessel density, macrophage infiltration extent, 
and TNF-α and interleukin-1β levels (IL-1β) in the ankle 
joint were evaluated. Nanogold was administered 
intra-articularly to rats with CIA before the onset of 
arthritis. Nanogold, bound to VEGF in case of RA,  
resulted in inhibition of synovial fluid, cell proliferation, 
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and migration in RA. A diminution in ankle 
circumference, articular index score, and radiographic 
scores were observed in the nanogold treated rats 
with CIA, compared to those in the untreated animals. 
Histologic analyses of cartilage erosion, leukocyte 
infiltration, synovial hyperplasia, macrophage infiltra-
tion, and TNF-α and IL-1β levels were found to be 
very low in the ankle joints of treated rats, which 
resulted in attenuation of arthritis. A study made by 
Chamberland et al. [88] investigated the potential of 
photoacoustic tomography in noninvasive monitoring 
of anti-TNF drug delivery, helped by Etanercept- 
conjugated AuNPs that were intra-articularly injected 
in model rats. Results showed that the viability of 
conjugated TNF antagonist pharmaceutical preparations 
with AuNPs preserve the mechanism of action of TNF 
antagonist as evaluated by photoacoustic tomography 
(PAT) technology with anti-rheumatic drugs. Another 
study analyzed the effect of HA and AuNPs on 
animal models of RA. In these animals of RA, local 
arthritic inflammation was clearly identified upon 
systematic injection of AuNPs. Results suggest that 
these nanoparticles can be used as in vivo optical 
imaging agents for detection of local HA-degrading 
disease, such as RA [89].  
Huang et al. [90] injected Galectin-1-nanogold (Au- 
GAL1) particles intra-articularly into rats with CIA. 
This conjugation promoted apoptosis of CD4+ T cells, 
decrease of pro-inflammatory cytokine levels in the 
ankle joints, and amelioration of clinical symptoms of 
arthritis.  
A study by Lee et al. [91] developed RGD-attached 
Au half-shell nanoparticles containing MTX to target 
chemo-photothermal for the treatment of RA. The 
RGD-attached Au half-shell nanoparticles containing 
MTX, combined with NIR radiation, showed a higher 
increase in therapeutic effect, than that with MTX in 
mice with CIA (Fig. 7). Finally, Lee et al. [92] studied 
the effect of hyaluronate-gold nanoparticle/Tocilizumab 
(HA-AuNP/TCZ) complex for the treatment of RA in 
CIA mouse model. AuNP has anti-angiogenic effect; 
TCZ is an antibody against the interleukin-6 (IL-6) 
receptor and utilized as an immunosuppressive drug 
by interfering with IL-6 in the pathogenesis of RA. 
HA has cartilage-protective and lubricant effect. In 
vitro results showed the binding of HA-AuNP/TCZ 
to VEGF and IL-6R, and therapeutic potential of 
HA-AuNP/TCZ (Fig. 8). 
Schulze et al. [93] investigated superparamagnetic 
iron oxide nanoparticles, coated with polyvinyl alcohol 
(PVA-SPIONS), which was intra-articularly applied 
in sheep model, and evaluated their uptake by synovial 
membrane. The uptake was completed in 48 h. The 
nanoparticles remained within the synovium for at 
least five days indicating that they could extend the 
action of intra-articularly applied medication for 
treating acute or chronic joint diseases. Another study 
investigated SPIONS, using magnetic resonance 
imaging (MRI), to track murine mesenchymal stem  
 
Figure 7 Schematic representation of the production process of 
RGD-MTX-PLGA AuNPs (reproduced with permission from Ref. 
[91], © American Chemical Society 2013). 
 
Figure 8 Schematic representation of HA-AuNP/TCZ complex 
for the treatment of RA (reproduced with permission from Ref. 
[92], © American Chemical Society 2014). 
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cells (MSCs) in vivo, labeled as SiMAG, in murine  
RA model. After RA introduction, the conjugate was 
implanted via articular injection, and joint swelling 
monitored as an indication of RA over days. A 
significant decrease in joint swelling was verified in 
groups containing SiMAG-labeled and unlabeled 
mMSCs, in presence of SPIONS does not affect the 
immunomodulating cells properties. This approach 
enabled the monitoring of migration of stem cell 
population within the rheumatic joint in a non- 
invasive way [3]. 
Kim et al. [94] investigated multimodal nanoparticles 
(MNP), containing Ru(bpy)3Cl2 core surrounded by a 
paramagnetic coating of gadolinium chelates, as a 
contrast agent of inflamed synovium in a CIA model. 
After intravenous administration of MNP, optical and 
magnetic resonance (MR) images were obtained and 
clinical disease was identified in MNP-labeled cells 
(monocytes/macrophages) within the inflamed joints. 
MR demonstrated a reduction in actively inflamed 
joints which was evident earlier, than during the 
course of the disease. MNP proved to be a potential 
modality contrast agent in inflammatory arthritis and 
localize to monocytes/macrophages within the inflamed 
synovium. 
Sekar [95] studied the azathioprine-loaded silver 
nanoparticles for RA treatment, using a green approach. 
In vitro toxicity of this conjugate was studied by means 
of a 3T3 NIH fibroblast cell line. This conjugate 
targets the disease site to release the drug in a 
controlled way and produce combined effect on the 
inflammatory sites. 
2.5 Other nanoparticle systems for treatment of RA 
There are various studies regarding the use of NPs 
for the treatment of RA; this includes solid lipid NPs 
and polymeric micelles (Table S5 in the ESM).  
Ye et al. [96] investigated the intravenous injection 
formulation of solid lipid nanoparticles (SLNs) loaded 
with actarit for improved therapeutic efficacy and 
reduced side-effects associated with its oral formulation 
in RA pathology. The actarit-loaded SLNs exhibited a 
longer mean retention time in vivo compared to that 
in 50% propylene glycol solution after intravenous  
injection in rabbits, and the targeting efficiency  
was enhanced in spleen while the renal distribution 
of actarit was reduced compared to that after an 
intravenous injection of actarit solution in mice. 
Therefore, this approach can promote passive targeting 
of therapeutic agents for treating RA. Another study 
explored the anti-inflammatory effect and hepatotoxicity 
of Tripterygium-loaded solid lipid nanoparticles 
(TWHF-SLN) in rats with AIA, and the effect of SLN 
delivery system on decreasing the TWHF-induced 
hepatotoxicity. After Freund’s complete adjuvant agent 
(FCA) injection, TWHF-SLN group and TWHF group 
were administered by oral gavage. The paws were 
evaluated for some days post-injection. Results showed 
that TWHF-SLN could greatly reduce rat paw volume. 
Histopathology showed that free TWHF caused more 
damage to the liver than TWHF-SLN, and the latter 
increased the anti-inflammatory effects [97].  
A study made by Nagai et al. [98] examined the 
effect of solid nanoparticle of indomethacin (IMC) on 
the treatment of rheumatoid arthritis in rats with AIA. 
The rats that received low doses of solid indomethacin 
nanoparticle after induction of paw edema had similar 
results as by the administration of a therapeutic dose 
of conventional IMC. There were less gastrointestinal 
lesions in the rats upon IMC nanoparticle administration 
compared to that with conventional IMC. These 
results showed that IMC nanoparticles may increase 
the efficiency of rheumatoid arthritis treatment without 
causing IMC-induced gastrointestinal lesions, because 
the bioavailability is more than in conventional IMC.  
αvβ3-targeted fumagillin nanoparticles that target 
angiogenesis to suppress inflammatory arthritis in 
mice were studied by Zhou et al. [99]. Arthritis was 
induced using K/BxN mouse model of inflammatory 
arthritis. After arthritis establishment, the mice received 
some doses of αvβ3-targeted fumagillin nanoparticles. 
The treated mice showed lower disease activity and 
change in ankle thickness compared to the group 
that received αvβ3-targeted fumagillin nanoparticles 
without drugs. There was a decrease in inflammation 
and angiogenesis in synovial tissues of animals treated 
with αvβ3-targeted fumagillin nanoparticles. 
Koo et al. [100] used sterically stabilized micelles 
(SSM) as nanocarriers for camptothecin CPT (CPT-SSM). 
In vitro studies showed that CPT inhibits synoviocyte 
proliferation, matrix metalloproteinase expression 
in chrondrocytes, and angiogenesis. The surface of 
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CPT-SSM was modified with vasoactive intestinal 
peptide (VIP) for active targeting. CPT was, for the first 
time, reported as effective against CIA, i.e. a single 
subcutaneous injection of CPT-SSM-VIP, administered 
to mice with CIA, alleviated joint inflammation for at 
least one month without systemic toxicity. However, 
CPT alone required a much higher dose in order to 
obtain the same effect. 
Table S6 in the ESM shows a summary of the main 
characteristics of the referred drugs and bioactive 
agents used for the treatment of rheumatoid arthritis 
[101, 102]. These data were mostly obtained from 
online databases of drugs [101] and proteins [102], in 
May 2016.  
3 Clinical trials  
Clinical trials are used to evaluate the safety and 
effectiveness of new treatments. ClinicalTrials.gov. is 
a website, maintained by the U.S. National Library of 
Medicine (NLM) at the National Institutes of Health 
(NIH), which provides access to a database with 
information on clinical studies, on a wide range of 
diseases and conditions. Information is provided and 
updated by the sponsor or principal investigator of 
the clinical study. A search on this database, using 
relevant keywords (such as “rheumatoid arthritis”, 
“nanoparticles”, “liposomes”, “polymeric nano-
particles”, or “dendrimers”) returned a single registered 
clinical trial related to the application of nano-
particles in RA management. This trial evaluated  
the safety of a single intravenous administration of 
long-circulating liposomal prednisolone disodium 
phosphate and compared it with pulse intramuscular 
methylprednisolone in patients with RA. This method 
is used in the clinics as a bridging therapy to assess 
the effect of this intervention at the synovial level. 
Liposomal corticosteroids increase efficacy/safety ratio, 
compared to corticosteroid administration. Although 
this study has been completed, no result was published 
on the database were the study was found [103]. 
4 Concluding remarks 
Several treatment alternatives that can be potentially 
used for the treatment of rheumatoid arthritis, 
instead of traditional drugs, have been reported. 
Nanotechnology (making use of nanoparticles) has 
been developed likewise for the treatment of rheumatoid 
arthritis. Most of the reported approaches exhibit great 
specificity in the delivery of the drug loaded-NPs to 
the site of action. These therapeutic strategies suggest 
an important potential to improve the efficacy and 
safety of rheumatoid arthritis therapeutics, with less 
toxicity and undesired side effects compared to that 
in traditional drugs (such as, DMARDs, NSAIDs, and 
corticosteroids). The small size and large surface area 
of NPs can lead to aggregation, which results in tough 
physical manipulation, limited drug loading, and 
burst release. Nevertheless, these limitations could be 
addressed by, for instance, a careful development of 
the drug delivery systems, surface modification, drug 
loading strategies, and release control.  
Most of the studied delivery systems in RA therapy 
involve liposomes. This type of NPs represents   
the most advanced way of carrier administration, as 
evidenced in animals and small clinical studies. 
Nevertheless, more research is needed to get better 
retention time and control the release rate of the 
encapsulated drug. 
Polymeric NPs also comprise a large part of the 
total studies conducted till date for the treatment of 
rheumatoid arthritis. The studies showed a remarkable 
positive effect, compared to free drugs. However, 
polymeric NPs are not as extensively studied as the 
liposomes for the treatment of RA. Therefore, further 
studies are needed to explore the potential of these 
nanoparticles. Recent studies, using dendrimers, 
demonstrated their great potential in the treatment of 
rheumatoid arthritis. Thus, further studies with such 
spherical NPs are needed in order to explore their 
promise further.  
Metallic nanoparticles also show great potential, 
but only few studies have been conducted till date to 
explore the accurate potential of these nanoparticles. 
Other studies reporting the application of nano-
particles for the treatment of rheumatoid arthritis have 
also shown positive results. Although much research 
is needed to clarify the underlying mechanisms of 
these therapeutic approaches, the results of recent 
studies confirm their promise in this regard due to 
their physicochemical and biological properties (such 
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as biocompatibility, low toxicity, controlled release, 
and selective drug delivery to inflamed tissues) in 
animal models with RA. 
Despite the encouraging results from most studies, 
some adjustments in these approaches are still required, 
especially with respect to efficacy and safety of the 
developed nanosystems, before being applied in 
humans. Nonetheless, it can be stated that advanced 
nanomaterials will certainly play a crucial role in the 
future, to develop nanopharmaceutics, and in particular, 
in patient-specific approaches for the treatment of 
human diseases such as RA.  
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